European natural gas prices rose more than 2% to €67.5 per megawatt-hour, the highest since January 2023, as investors awaited details of a US plan to economically isolate Iran that could further disrupt energy supplies from the Middle East.
Gold rose to around $4,630 an ounce on Monday, extending last week's gains and reaching its highest level since mid-May, as concerns over US debt management and fiscal sustainability persisted following the Treasury's unexpected ramp-up in longer-dated debt buybacks.
Silver traded above $69 an ounce on Monday, hovering at a two-month high, as concerns over USDebtmanagement and fiscal sustainability persisted after the Treasury unexpectedly ramped up buybacks of longer-dated government debt.
Coal prices rose above $131 per ton in late August, reaching their highest level since early August, amid firm Asian energy demand and ongoing supply risks.
Telix Pharmaceuticals Limited (NASDAQ: TLX) shares closed down 9% at $11.33 despite reporting 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million.
Seres Therapeutics, Inc. (NASDAQ: MCRB) pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit, primarily fueled by a $25 million gain tied to VOWST and reduced overhead.
Decoy Therapeutics reported a 148% expansion in Q2 net losses to $2.37 million, primarily attributed to intensified R&D investments following the IMP3ACT program merger and legacy expenditure.
Senti Biosciences, Inc. (NASDAQ: SNTI) shares closed down 11% at $0.39 afterSubsidiarySenti Holdings finalized a $4 million senior secured convertible note issuance to Celadon Partners SPV 24.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) shares closed up 15% at $15.46 after Maxim reiterated its Buy rating and $30 price target, notably above the $27.50 market consensus.
Telix Pharmaceuticals Limited (NASDAQ: TLX) reported 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million, driven by robust product sales and a $40 million collaboration milestone from Regeneron.